Baseline characteristics

Sorafenib in Treating Patients With Regional or Metastatic Cancer of the Urothelium · Source last updated 2014-05-30

Results reported by the registry submitting party. Population, time horizon, units and missing values must be read together.

denoms

1. counts

   1. group Id

      BG000

      value

      22

   units

   Participants

groups

1. description

   Only eligible and treated patients are included in the analysis. BAY 43-9006 was administered at a dose of 400 mg orally twice daily (total daily dose 800 mg) for eight weeks as one cycle. Patients swallowed the tablets whole with approximately 250 ml (8 oz.) of water each morning and evening (i.e., 12-hourly), with or without food. If Bay 43-9006 was taken with meals, patients were instructed to take BAY 43-9006 tosylate with a moderate to low-fat meal, as a high fat meal caused a decrease in absorption in previous studies.

   id

   BG000

   title

   TCC Cohort

measures

1. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            lower Limit

            37

            upper Limit

            81

            value

            66

   dispersion Type

   FULL_RANGE

   param Type

   MEDIAN

   title

   Age, Continuous

   unit Of Measure

   years

2. classes

   1. categories

      1. measurements

         1. group Id

            BG000

            value

            8

         title

         Female

      2. measurements

         1. group Id

            BG000

            value

            14

         title

         Male

   description

   Gender of eligible participants who began treatment.

   param Type

   COUNT_OF_PARTICIPANTS

   title

   Sex: Female, Male

   unit Of Measure

   Participants

Download exact source JSON → · Snapshot ctgov-results-25a395029948b04d52b1253f

Preserved source evidence · Not medical advice